MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2018 International Congress

    Economics of Botulinum Toxin Therapy: Influence of the AbobotulinumtoxinA Package Size on the Costs of Botulinum Toxin Therapy

    F. Adib Saberi, D. Dressler (Hamburg, Germany)

    Objective: To explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic (>9000…
  • 2018 International Congress

    Botulinum toxin injection for Pisa syndrome in Parkinson’s disease

    CA. Artusi, M. Zibetti, P. Barbero, M. Busso, S. Bortolani, S. De Mercanti, P. Arnoffi, M. Fabbri, A. Merola, L. Lopiano (Torino, Italy)

    Objective: We sought to assess the clinical efficacy of Botulinum toxin (BoNT) injection for Pisa syndrome (PS) using a combined Magnetic Resonance Imaging (MRI)-, Ultrasonography…
  • 2018 International Congress

    Effects of Botulinum Toxin treatment for sialorrhea in patients with cerebral palsy

    J. Francês Brito, M. Akkari, A. Pinheiro Alves, A. Barbosa de Sousa Junior, B. De Oliveira, O. Vieira Kishi, Jose Roberto Bentes Capeloni (Belem, Brazil)

    Objective: To evaluate the benefits of treatment of drooling with Botulinum Toxin Type A (AbobotulinumtoxinA) in patients with cerebral palsy. Background: Patients with cerebral palsy…
  • 2018 International Congress

    Botulinum toxin A (BoNT A) treatment of postsurgical/posttraumatic focal movements not responding to oral therapy

    A. Lozza, A. Castagna, G. Castelnovo, E. Alfonsi, A. Montini, L. Marchetta, M. Fresia, A. Arrigo, R. Manni (Pavia, Italy)

    Objective: We report three cases of focal movement disorder following trauma or surgery. Oral therapies were ineffective in both patients and symptoms dramatically improved after…
  • 2018 International Congress

    Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series

    C. Wang, E. Wang, H. Lei (Tucson, AZ, USA)

    Objective: To report increased risks of Botulinum Toxin Injection for cervical dystonia and migraine in patients with Hypermobility Ehlers Danlos Syndrome. Background: Ehlers-Danlos syndrome (EDS)…
  • 2018 International Congress

    Botulinum toxin in Restless Leg Syndrome – A Randomized Double-Blind Placebo-Controlled Study

    S. Mittal, D. Machado, D. RIchardson, D. Dubey, B. Jabbari (Bangalore, India)

    Objective: To study the efficacy of incobotulinumtoxin A (IncoA) in relieving the symptoms of restless legs syndrome (RLS) Background: RLS is a common movement disorder…
  • 2018 International Congress

    Incobotulinum toxin type A for the treatment of biceps/triceps co-contraction due to obstetrical brachial plexus lesion

    G. Ianieri, R. Marvulli, G. Gallo (Bari, Italy)

    Objective: The injection of Incobotulinum toxin type A associated with physical therapy may improve the kinematics of flexion and extension of the elbow after obstetrical…
  • 2017 International Congress

    Efficacy and safety of incobotulinumtoxinA (inco/A) for essential tremor using kinematics-guided clinical decision support: A randomized, double-blind, placebo-controlled trial

    M. Jog, J. Lee, M. Althaus, A. Scheschonka, H. Dersch, E.T. Study Team, D. Simpson (London, ON, Canada)

    Objective: To demonstrate improvement of arm tremor severity and hand function with kinematics-guided inco/A therapy Background: Botulinum neurotoxin A (BoNT-A) therapy of debilitating tremor symptoms…
  • 2017 International Congress

    Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm

    A. Wagle Shukla, J. Legacy, W. Deeb, W. Hu (Gainesville, FL, USA)

    Objective: To determine whether repetitive transcranial magnetic stimulation (rTMS) of anterior cingulate cortex (ACC) when added to botulinum toxin (BoNT) therapy improves benign essential blepharospasm…
  • 2017 International Congress

    Differences between Hemifacial spasm with or without neurovascular conflict. Therapeutic implications with botulinum toxin type A.

    J.S. Bestoso, L. Ciancaglini, C. Stefani, C. Azcona, M.L. Contartese, A. Pappolla, J.I. Rojas, D. Bauso (Buenos Aires, Argentina)

    Objective: To evaluate the presence of possible clinical differences between patients with HS with and without neurovascular conflict (NVC +, NVC-) and their therapeutic response…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley